Propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis

Kidney International

Volumn 69, Issue 8, 2006, Pages 1477-1481

  Zhao, M H ^a   Chen, M ^a   Gao, Y ^a   Wang, H Y ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTINUCLEAR ANTIBODY; AZUROCIDIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GLOMERULUS BASEMENT MEMBRANE ANTIBODY; IMMUNOSUPPRESSIVE AGENT; LACTOFERRIN; LIOTHYRONINE; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PROPYLTHIOURACIL; THIAMAZOLE; THYROTROPIN; THYROXINE;

ABNORMAL RESPIRATORY SOUND; ADULT; ANCA ASSOCIATED VASCULITIS; ARTHRALGIA; ARTICLE; CASE REPORT; CHINA; COUGHING; DRUG DOSE REGIMEN; EXOPHTHALMOS; EYE DISEASE; FEMALE; GLOMERULONEPHRITIS; GOITER; GRAVES DISEASE; HEARING IMPAIRMENT; HEMATURIA; HEMOPTYSIS; HUMAN; HUMAN TISSUE; HYPERTHYROIDISM; LUNG HEMORRHAGE; MYALGIA; PALLOR; PATHOGENESIS; PRIORITY JOURNAL; RASH; SIDE EFFECT; SYSTEMIC VASCULITIS; TACHYCARDIA; THORAX RADIOGRAPHY; THYROIDECTOMY; WEIGHT REDUCTION; WHEEZING;

ADULT; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; BIOPSY; FEMALE; FOLLOW-UP STUDIES; GLOMERULONEPHRITIS; HUMANS; HYPERTHYROIDISM; NECROSIS; PLASMAPHERESIS; PROPYLTHIOURACIL; RADIOGRAPHY, THORACIC; TIME FACTORS; TREATMENT OUTCOME; VASCULITIS;

EID: 33646159977     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000387     Document Type: Article

References (20)

1. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculities: proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-192.
2. Falk RJ, Terrell RS, Charles LA et al. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990; 87: 4115-4119.
3. Falk RJ, Jennette JC. ANCA are pathogenic - oh yes they are!. J Am Soc Nephrol 2002; 13: 1977-1979.
4. Sera N, Ashizawa K, Ando T et al. Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves' disease. Thyroid 2000; 10: 595-599.
5. Wada N, Mukai M, Kohno M et al. Prevalence of serum anti-myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) in patients with Graves' disease treated with propylthiouracil and thiamazole. Endocr J 2002; 49: 329-334.
6. Harper L, Chin L, Daykin J et al. Propylthiouracil and carbimazole associated-antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves' disease. Clin Endocrinol (Oxf) 2004; 60: 671-675.
7. Fujieda M, Hattori M, Kurayama H, et al., Members and Coworkers of the Japanese Society for Pediatric Nephrology. Clinical features and outcomes in children with antineutrophil cytoplasmic autoantibody-positive glomerulonephritis associated with propylthiouracil treatment. J Am Soc Nephrol 2002; 13: 437-445.
8. Gao Y, Zhao MH, Guo XH et al. The prevalence and target antigens of antithyroid drugs induced antineutrophil cytoplasmic antibodies (ANCA) in Chinese patients with hyperthyroidism. Endocr Res 2004; 30: 1-9.
9. Dolman KM, Gans RO, Vervaat TJ et al. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet 1993; 342: 651-652.
10. Slot MC, Links TP, Stegeman CA et al. Occurrence of antineutrophil cytoplasmic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: a long-term followup study. Arthritis Rheum 2005; 53: 108-113.
11. Ye H, Zhao MH, Gao Y et al. Anti-myeloperoxidase antibodies in sera from patients with propylthiouracil induced vasculitis might recognize restricted epitopes on myeloperoxidase molecule. Clin Exp Immunol 2004; 138: 179-182.
12. Ye H, Gao Y, Guo XH et al. Titer and affinity of propylthiouracil-induced anti-myeloperoxidase antibodies are closely associated with the development of clinical vasculitis. Clin Exp Immunol 2005; 142: 116-119.
13. Gao Y, Ye H, Yu F et al. Anti-myeloperoxidase IgG subclass distribution and avidity in sera from patients with propylthiouracil induced antineutrophil cytoplasmic antibodies associated vasculitis. Clin Immunol 2005; 117: 87-93.
14. Cid MC, Segarra M, Garcia-Martinez A et al. Endothelial cells, antineutrophil cytoplasmic antibodies, and cytokines in the pathogenesis of systemic vasculitis. Curr Rheumatol Rep 2004; 6: 184-194.
15. D'Cruz DP, Keser G, Direskeneli H et al. Anti-endothelial cell antibodies in systemic vasculitis and systemic lupus erythematosus (SLE): effects of heat inactivation on binding and specificity. Clin Exp Immunol 1999; 115: 567-570.
16. Yu F, Zhao MH, Zhang YK et al. Anti-endothelial cell antibodies (AECA) in patients with propylthiouracil induced ANCA positive vasculitis are associated with disease activity. Clin Exp Immunol 2005; 139(3): 569-574.
17. Lee E, Hirouchi M, Hosokawa M et al. Inactivation of peroxidases of rat bone marrow by repeated administration of propylthiouracil is accompanied by a change in the heme structure. Biochem Pharmacol 1988; 37: 2151-2153.
18. Jiang X, Khursigara G, Rubin RL. Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science 1994; 266: 810-813.
19. Xu XD, Zhao MH, Zhang YK et al. Clinico-pathological characteristics of propylthiouracil-induced anti-neutrophil cytoplasmic antibodies positive vasculitis and their target antigens: a report of 4 cases and literature review. Zhong Hua Nei Ke Za Zhi 2002; 41: 404-407.
20. Gunton JE, Stiel J, Caterson RJ et al. Clinical case seminar: anti-thyroid drugs and antineutrophil cytoplasmic antibody positive vasculitis. A case report and review of the literature. J Clin Endocr Metab 1999; 84: 13-16.